Evidence map›Paper›PMID 35968812›Full record

ArticleThe EMBO journal2022

Vaginal bacterium Prevotella timonensis turns protective Langerhans cells into HIV-1 reservoirs for virus dissemination.

Nienke H van Teijlingen, Leanne C Helgers, Ramin Sarrami-Forooshani, Esther M Zijlstra-Willems, John L van Hamme, Celia Segui-Perez, Marleen Y van Smoorenburg, Hanneke Borgdorff, Janneke Hhm van de Wijgert, Elisabeth van Leeuwen and 4 more

Open access · bronzeAbstract read
In one paragraph

Article in The EMBO journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Anaerobe-Driven Inflammation and Epithelial Barrier Disruption in Genital HIV Acquisition.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  3. Innate Immune Protection Against HIV in the Female Genital Tract.American journal of reproductive immunology (New York, N.Y. : 1989) · 2026
    Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. mBio · 2024
    Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Nienke H van Teijlingen *Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5693-1619
Leanne C Helgers *Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-1200-2225
Ramin Sarrami-ForooshaniDepartment of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Esther M Zijlstra-WillemsDepartment of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
John L van HammeDepartment of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-0765-9441
Celia Segui-PerezDivision Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, The Netherlands.ORCID 0000-0003-1977-3946
Marleen Y van SmoorenburgDepartment of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Hanneke BorgdorffAmsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands.
Janneke Hhm van de WijgertJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, The Netherlands.
Elisabeth van LeeuwenDepartment of Obstetrics and Gynecology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0003-2463-9127
Joris Am van der PostDepartment of Obstetrics and Gynecology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.
Karin Strijbis *Division Infectious Diseases and Immunology, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, University of Utrecht, Utrecht, The Netherlands.ORCID 0000-0001-9167-7137
Carla Ms Ribeiro *Department of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5682-4143
Teunis Bh GeijtenbeekDepartment of Experimental Immunology, Amsterdam UMC Location University of Amsterdam, Amsterdam, The Netherlands.ORCID 0000-0002-5710-2839
Amsterdam University Medical Centers · NLUniversity of Applied Sciences Utrecht · NLAcademic Center for Education, Culture and Research · IRAmsterdam Institute for Global Health and Development · NLUniversity Medical Center Utrecht · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dysbiosis of vaginal microbiota is associated with increased HIV-1 acquisition, but the underlying cellular mechanisms remain unclear. Vaginal Langerhans cells (LCs) protect against mucosal HIV-1 infection via autophagy-mediated degradation of HIV-1. As LCs are in continuous contact with bacterial members of the vaginal microbiome, we investigated the impact of commensal and dysbiosis-associated vaginal (an)aerobic bacterial species on the antiviral function of LCs. Most of the tested bacteria did not affect the HIV-1 restrictive function of LCs. However, Prevotella timonensis induced a vast uptake of HIV-1 by vaginal LCs. Internalized virus remained infectious for days and uptake was unaffected by antiretroviral drugs. P. timonensis-exposed LCs efficiently transmitted HIV-1 to target cells both in vitro and ex vivo. Additionally, P. timonensis exposure enhanced uptake and transmission of the HIV-1 variants that establish infection after sexual transmission, the so-called Transmitted Founder variants. Our findings, therefore, suggest that P. timonensis might set the stage for enhanced HIV-1 susceptibility during vaginal dysbiosis and advocate targeted treatment of P. timonensis during bacterial vaginosis to limit HIV-1 infection.

Indexed as

HIV-1HIV InfectionsAntiviral AgentsDysbiosisFemaleHumansLangerhans CellsPrevotellaAntiviral AgentsHIV-1Langerhans cells (LCs)Prevotella timonensistransmissionvaginal microbiome

Identifiers

PMID35968812
PMCPMC9531304
OpenAlexW4291553525

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.